NEW YORK (GenomeWeb) – In a filing with the US Securities and Exchange Commission last week, CareDx announced that its CareDx Pty subsidiary had agreed to purchase from Illumina affiliate Conexio Genomics certain property and assets related to HLA typing for sequencing using capillary electrophoresis-based methods.
CareDx Pty will pay up to $232,792 for finished goods, $156,159 for unfinished inventory, and will make quarterly payments to Conexio in an amount equal to 20 percent of the gross revenue from the sale of products using assets purchased in the acquisition up to $735,000. CareDx Pty will further assume all obligations under the lease of Conexio facilities and will assume all liabilities for product warranty claims up to $35,000.
In return, Conexio has agreed to indemnify CareDx Pty and its affiliates against certain losses related to possible breaches of Conexio's representations and warranties, among other things.
CareDx Pty and Conexio have also agreed to enter into a license agreement under which Conexio will grant CareDx Pty a license to use certain software, technology, and trademarks still owned by Conexio. Illumina has also agreed to provide CareDx Pty with access to the services of one of its employees for 12 months to assist with the transfer of manufacturing operations and overall expertise associated with the assets purchased.
In an email to GenomeWeb, Illumina noted that it will continue to sell its TruSight HLA solution, along with the Assign analysis software originally developed by Conexio prior to its acquisition by Illumina in January 2016.